Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China

Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China

IntroductionIn October 2017, China initiated adjustments to the registration procedures for imported drugs to promote accessibility to overseas drugs. In support of this decision, the National Medical Products Administration (NMPA) issued a technical guideline regarding accepting foreign clinical tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengjuan Jiang, Jingjing Huang, Su Wang, Yulu Fan, Yuwen Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Public Health
Subjects:
foreign clinical data
innovation investment
difference-in-differences model
pharmaceutical firms
absorptive capacity
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2025.1512148/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items